ライフサイエンスコーパス: SSEA-1

1 SSEA-1(+) PSCs reduced AHR and airway damage in asthmati

2 ct4) and stage-specific embryonic antigen 1 (SSEA-1), as well as the epithelial markers pancytokerati

3 protein, stage-specific embryonic antigen 1 (SSEA-1).

4 Stage-specific embryonic antigen-1 (SSEA-1)(+) endometrial epithelial cells (EECs) assume th

5 xpressed stage-specific embryonic antigen-1 (SSEA-1), and all were ICAM-2(-) and CD34(-), whereas vas

6 ct4) and stage-specific embryonic antigen-1 (SSEA-1), the alveolar stem cell marker Clara cell secret

7 ssion of stage-specific embryonic antigen-1 (SSEA-1).

8 d down by ERK5 siRNA, reduction of Oct-4 and SSEA-1 expression was rescued.

9 cell-surface molecules Ephb2, ephrin B2 and SSEA-1 (Fut4) have been correlated to the normally devel

10 ssels were PECAM(+), ICAM-2(+), CD34(+), and SSEA-1(-).

11 nti-stage specific embryonic antigen-1 (anti-SSEA-1) is an injectable IgM antibody derived from mice.

12 The antibody, anti-SSEA-1, chosen from studies of 10 neutrophil-specific MA

13 poly-N-acetyllactosamine recognized by anti-SSEA-1; (ii) insights into chondroitin sulfate oligosacc

14 easure biodistribution of 99mTc-labeled anti-SSEA-1 and perform radiation dosimetry in 10 healthy hum

15 ion of the stage-specific embryonic antigen, SSEA-1 (also known as the Lewis X antigen or LeX), which

16 o germline stem cells could be identified by SSEA-1 immunostaining, the stem cell model was tested us

17 These cells express the surface antigen CD15/SSEA-1 and have elevated levels of genes associated with

18 n antigen, sialyl Lewis C, and Lewis X (CD15/SSEA-1).

19 n vitro EEC organoid models also demonstrate SSEA-1(+) EECs to exhibit estrogen responsive proliferat

20 e included populations that expressed either SSEA-1(+) or Sca-1(+) (stem cell antigen-1).

21 from Atoh1 expressing RP progenitors express SSEA-1, and in the absence of Atoh1 these progenitors be

22 scent, less hormone responsive phenotype for SSEA-1(+) EECs that co-localize to SOX9(+) EECs within i

23 , the porcine iPSC (piPSC) were positive for SSEA-1, but negative for SSEA-3 and -4.

24 es (fucosyl-Lc4Cer) to neolacto-series GSLs (SSEA-1 and H type 2 antigen), along with marked down-reg

25 BMP2-induced SSEA-1+ cells were purified from ES and iPS cells and co

26 esent the transcriptomic profile of isolated SSEA-1(+) EECs from eight endometrial biopsies compared

27 ious studies have demonstrated that isolated SSEA-1(+) cells have a higher capacity to generate organ

28 ainst a panel of five immunological markers (SSEA-1, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81) that hav

29 s major ES cell markers such as Oct4, Nanog, SSEA-1, alkaline phosphatase, and SALL4.

30 Enriched neonatal SSEA-1(+) PSCs had the ability of self-renewal and diffe

31 tanding the molecular mechanisms of neonatal SSEA-1(+) PSCs might shed light on exploring the novel t

32 Here, we demonstrated that neonatal SSEA-1(+) PSCs play an immunomodulatory role in the prog

33 ved that expressed pluripotent markers Oct4, SSEA-1, Rex1, and AP and hemangioblast markers CD133, Fl

34 Characterization of SSEA-1+ mesenchymal cells revealed that upon purificatio

35 The effects of SSEA-1(+) (stage-specific embryonic antigen-1) PSCs was

36 T-transduced ES cells exhibit a low level of SSEA-1 surface antigen and alkaline phosphatase staining

37 tion of the mesenchymal compartment, placing SSEA-1+ cells at the apex of this hierarchy.

38 scriptome and pathway analysis indicate that SSEA-1(+) EECs play an important role in endometrial reg

39 We show that SSEA-1(+) EECs play a role in endometrial tissue homeost

40 The SSEA-1(+) PSCs were highly prevalent in neonatal mice, a

41 Also, these SSEA-1+ cells have a much higher capacity to differentia

42 from eight endometrial biopsies compared to SSEA-1(-) EECs.

43 t upon purification these cells gave rise to SSEA-1- mesenchymal cells, whereas the reverse could not